Gelfand, Joel M.Armstrong, April W.Bell, StacieAnesi, George L.Blauvelt, AndrewCalabrese, CassandraDommasch, Erica D.Feldman, Steven R.Gladman, DafnaKircik, LeonLebwohl, MarkLo Re, Vincent, IIIMartin, GeorgeMerola, Joseph F.Scher, Jose U.Schwartzman, SergioTreat, James R.Van Voorhees, Abby S.Ellebrecht, Christoph T.Fenner, JustineOcon, AnthonySyed, Maha N.Weinstein, Erica J.Gondo, GeorgeHeydon, SueKoons, SamanthaRitchlin, Christopher T.2021-04-292021-04-292021-05Gelfand, J. M., Armstrong, A. W., Bell, S., Anesi, G. L., Blauvelt, A., Calabrese, C., ... & Ritchlin, C. T. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 2–Advances in Psoriatic Disease Management, COVID-19 Vaccines, and COVID-19 Treatments. Journal of the American Academy of Dermatology, 84(5), 1254-1268. https://doi.org/10.1016/j.jaad.2020.12.058https://hdl.handle.net/1805/25816This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Objective To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic. Study Design The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff. Clinical questions relevant to the psoriatic disease community were informed by inquiries received by the National Psoriasis Foundation. A Delphi process was conducted. Results The TF updated evidence for the original 22 statements and added 5 new recommendations. The average of the votes was within the category of agreement for all statements, 13 with high consensus and 14 with moderate consensus. Limitations The evidence behind many guidance statements is variable in quality and/or quantity. Conclusions These statements provide guidance for the treatment of patients with psoriatic disease on topics including how the disease and its treatments affect COVID-19 risk, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 (including novel vaccination), and what they should do if they develop COVID-19. The guidance is a living document that is continuously updated by the TF as data emerge.enPublic Health EmergencybiologicsCOVID-19psoriasisArticle